CVRx (NASDAQ:CVRX) Upgraded at William Blair

William Blair upgraded shares of CVRx (NASDAQ:CVRX) from a market perform rating to an outperform rating in a report issued on Tuesday morning, MarketBeat.com reports. William Blair also issued estimates for CVRx’s Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($2.62) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.82) EPS.

A number of other equities analysts have also recently weighed in on CVRX. Craig Hallum upped their price objective on shares of CVRx from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Lake Street Capital upped their price target on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $14.00 price objective on shares of CVRx in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.67.

CVRx Stock Performance

Shares of CVRX opened at $17.30 on Tuesday. CVRx has a 12 month low of $6.40 and a 12 month high of $29.23. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. The firm has a market cap of $419.70 million, a PE ratio of -6.41 and a beta of 1.26. The stock has a fifty day moving average price of $14.04 and a 200-day moving average price of $11.05.

CVRx (NASDAQ:CVRX) last released its earnings results on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. The firm had revenue of $13.37 million for the quarter, compared to analyst estimates of $13.28 million. During the same period last year, the firm earned ($0.43) EPS. Equities research analysts predict that CVRx will post -2.62 earnings per share for the current fiscal year.

Institutional Trading of CVRx

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in shares of CVRx in the third quarter valued at about $108,000. XTX Topco Ltd purchased a new position in shares of CVRx in the 3rd quarter worth about $150,000. Jane Street Group LLC raised its holdings in CVRx by 36.1% in the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after buying an additional 5,053 shares during the period. Barclays PLC increased its holdings in CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after purchasing an additional 14,445 shares in the last quarter. Finally, Centiva Capital LP acquired a new stake in CVRx in the third quarter valued at approximately $178,000. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.